NewAmsterdam Pharma dosed first participant in SPINOZA Phase 2b trial of obicetrapib

NewAmsterdam Pharma dosed the first participant in SPINOZA, a Phase 2b trial of obicetrapib in preclinical Alzheimer’s disease. The 52-week study tracks whether treatment shifts Alzheimer’s-related blood biomarkers; about 400 participants will receive obicetrapib 10 mg or placebo, with an optional 26-week extension on active drug.